Updates in Drug Treatment of Severe Hypertriglyceridemia

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2023 Aug 29

PMID 37642858

Authors

Ioanna Gouni-Berthold

Jonas Schwarz

Heiner K Berthold

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To provide an insight into the new pharmacological options for the treatment of severe hypertriglyceridemia (sHTG).

Recent Findings: sHTG is difficult to treat. The majority of the traditional pharmacological agents available have limited success in both robustly decreasing triglyceride levels and/or in reducing the incidence of acute pancreatitis (AP), the most severe complication of sHTG. Therapeutic options with novel mechanisms of action have been developed, such as antisense oligonucleotides (ASO) and small interfering RNA (siRNA) targeting APOC3 and ANGPTL3. The review discusses also 2 abandoned drugs for sHTG treatment, evinacumab and vupanorsen. The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndrome (FCS) in Europe. Olezarsen, an N-acetylgalactosamine (GalNAc)-conjugated ASO with the same target, seems to have a better safety and efficacy profile. siRNA targeting APOC3 and ANGPTL3, namely ARO-APOC3 and ARO-ANG3, are also promising for the treatment of sHTG. However, the ultimate clinical goal of any sHTG treatment, the decrease in the risk of AP, has not been definitively achieved till now by any pharmacotherapy, either approved or in development.

Citing Articles

Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review.

Zimodro J, Rizzo M, Gouni-Berthold I Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005962 PMC: 11858358. DOI: 10.3390/ph18020147.

Lipids dysregulation in diseases: core concepts, targets and treatment strategies.

Dakal T, Xiao F, Bhusal C, Sabapathy P, Segal R, Chen J Lipids Health Dis. 2025; 24(1):61.

PMID: 39984909 PMC: 11843775. DOI: 10.1186/s12944-024-02425-1.

The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization.

Zheng Q, Lin R, Wang D, Chen R, Xu W BMC Musculoskelet Disord. 2025; 26(1):107.

PMID: 39893413 PMC: 11787747. DOI: 10.1186/s12891-024-08160-z.

An unusual case of type I hyperlipidemia - infant with acute encephalopathy, bulging fontanel, vomiting and pink blood: a case report.

Kalanj J, Cobeljic M, Jesic M, Zdravkovic V, Cvetkovic M, Vukasinovic N BMC Pediatr. 2024; 24(1):815.

PMID: 39696078 PMC: 11656882. DOI: 10.1186/s12887-024-05287-9.

Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.

References

McGarrah R, Craig D, Haynes C, Dowdy Z, Shah S, Kraus W . High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis. 2016; 246:229-35. PMC: 4764426. DOI: 10.1016/j.atherosclerosis.2016.01.012. View

Witztum J, Gaudet D, Arca M, Jones A, Soran H, Gouni-Berthold I . Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. J Clin Lipidol. 2023; 17(3):342-355. DOI: 10.1016/j.jacl.2023.03.007. View

Dewey F, Gusarova V, Dunbar R, ODushlaine C, Schurmann C, Gottesman O . Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017; 377(3):211-221. PMC: 5800308. DOI: 10.1056/NEJMoa1612790. View

Peloso G, Auer P, Bis J, Voorman A, Morrison A, Stitziel N . Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet. 2014; 94(2):223-32. PMC: 3928662. DOI: 10.1016/j.ajhg.2014.01.009. View

Digenio A, Dunbar R, Alexander V, Hompesch M, Morrow L, Lee R . Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care. 2016; 39(8):1408-15. DOI: 10.2337/dc16-0126. View

Christian J, Arondekar B, Buysman E, Johnson S, Seeger J, Jacobson T . Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012; 6(5):450-61. DOI: 10.1016/j.jacl.2012.08.007. View

Gouni-Berthold I, Alexander V, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty P . Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021; 9(5):264-275. DOI: 10.1016/S2213-8587(21)00046-2. View

Paquette M, Bernard S . The Evolving Story of Multifactorial Chylomicronemia Syndrome. Front Cardiovasc Med. 2022; 9:886266. PMC: 9046927. DOI: 10.3389/fcvm.2022.886266. View

Ng D . Evolving ANGPTL-based lipid-lowering strategies and beyond. Curr Opin Lipidol. 2021; 32(4):271-272. DOI: 10.1097/MOL.0000000000000764. View

10.

Crosby J, Peloso G, Auer P, Crosslin D, Stitziel N, Lange L . Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014; 371(1):22-31. PMC: 4180269. DOI: 10.1056/NEJMoa1307095. View

11.

Spagnuolo C, Hegele R . Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Expert Opin Pharmacother. 2023; 24(9):1013-1020. DOI: 10.1080/14656566.2023.2206015. View

12.

Witztum J, Gaudet D, Freedman S, Alexander V, Digenio A, Williams K . Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019; 381(6):531-542. DOI: 10.1056/NEJMoa1715944. View

13.

Graham M, Lee R, Brandt T, Tai L, Fu W, Peralta R . Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017; 377(3):222-232. DOI: 10.1056/NEJMoa1701329. View

14.

Bergmark B, Marston N, Bramson C, Curto M, Ramos V, Jevne A . Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022; 145(18):1377-1386. PMC: 9047643. DOI: 10.1161/CIRCULATIONAHA.122.059266. View

15.

Wolska A, Yang Z, Remaley A . Hypertriglyceridemia: new approaches in management and treatment. Curr Opin Lipidol. 2020; 31(6):331-339. PMC: 7770610. DOI: 10.1097/MOL.0000000000000710. View

16.

Lazarte J, Hegele R . Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Rev Cardiovasc Ther. 2021; 19(8):685-693. DOI: 10.1080/14779072.2021.1955348. View

17.

Shamsudeen I, Hegele R . Safety and efficacy of therapies for chylomicronemia. Expert Rev Clin Pharmacol. 2022; 15(4):395-405. DOI: 10.1080/17512433.2022.2094768. View

18.

Tardif J, Karwatowska-Prokopczuk E, Amour E, Ballantyne C, Shapiro M, Moriarty P . Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022; 43(14):1401-1412. PMC: 8986458. DOI: 10.1093/eurheartj/ehab820. View

19.

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

20.

Rosenson R, Gaudet D, Ballantyne C, Baum S, Bergeron J, Kershaw E . Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023; 29(3):729-737. PMC: 10033404. DOI: 10.1038/s41591-023-02222-w. View